Today, Gilead Sciences Inc. (GILD) Stake Decreased by E&G Advisors LP

Today, Gilead Sciences Inc. (GILD) Stake Decreased by E&G Advisors LP

E&G Advisors LP lowered its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 3.8% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 28,041 shares of the biopharmaceutical company’s stock after selling 1,100 shares during the period. Gilead Sciences accounts for approximately 1.3% of E&G Advisors LP’s holdings, making the stock its 14th largest position. E&G Advisors LP’s holdings in Gilead Sciences were worth $2,219,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bank of New York Mellon Corp boosted its position in shares of Gilead Sciences by 4.0% in the second quarter. Bank of New York Mellon Corp now owns 26,617,229 shares of the biopharmaceutical company’s stock worth $2,220,410,000 after buying an additional 1,023,299 shares in the last quarter. BlackRock Fund Advisors boosted its position in shares of Gilead Sciences by 2.6% in the second quarter. BlackRock Fund Advisors now owns 24,369,287 shares of the biopharmaceutical company’s stock worth $2,032,886,000 after buying an additional 612,544 shares in the last quarter. Capital World Investors boosted its position in shares of Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock worth $1,277,907,000 after buying an additional 3,380,000 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Gilead Sciences by 17.0% in the second quarter. Alliancebernstein L.P. now owns 13,346,714 shares of the biopharmaceutical company’s stock worth $1,113,383,000 after buying an additional 1,942,138 shares in the last quarter. Finally, Parnassus Investments CA boosted its position in shares of Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock worth $705,774,000 after buying an additional 2,640,284 shares in the last quarter. Hedge funds and other institutional investors own 73.59% of the company’s stock.

Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.19% during mid-day trading on Monday, hitting $74.54. 9,338,882 shares of the stock were exchanged. The stock has a 50 day moving average of $74.54 and a 200-day moving average of $80.07. The stock has a market cap of $98.20 billion, a price-to-earnings ratio of 6.89 and a beta of 1.25. Gilead Sciences Inc. has a 52-week low of $71.39 and a 52-week high of $107.38.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $2.75 EPS for the quarter, missing the consensus estimate of $2.87 by $0.12. The firm had revenue of $7.40 billion for the quarter, compared to analysts’ expectations of $7.47 billion. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The firm’s quarterly revenue was down 9.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.22 earnings per share. Equities analysts predict that Gilead Sciences Inc. will post $11.47 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 2.53%. The ex-dividend date of this dividend is Tuesday, December 13th. Gilead Sciences’s payout ratio is 17.44%.

GILD has been the subject of a number of analyst reports. Credit Suisse Group AG reduced their price objective on shares of Gilead Sciences from $115.00 to $95.00 and set an “outperform” rating for the company in a report on Wednesday, September 14th. Jefferies Group reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday, August 25th. Piper Jaffray Cos. reissued an “overweight” rating and set a $108.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 31st. RBC Capital Markets dropped their price target on shares of Gilead Sciences from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 2nd. Finally, Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, September 14th. Ten investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $97.90.

In other Gilead Sciences news, Director John W. Madigan sold 105,000 shares of Gilead Sciences stock in a transaction on Friday, November 18th. The shares were sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the completion of the transaction, the director now directly owns 121,761 shares of the company’s stock, valued at $9,115,028.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John F. Milligan sold 70,000 shares of Gilead Sciences stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $77.74, for a total transaction of $5,441,800.00. Following the transaction, the insider now directly owns 1,128,963 shares of the company’s stock, valued at $87,765,583.62. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Related posts

Leave a Comment